Microsomal Triglyceride Transfer Protein Inhibitors
Approved in December 2012, lomitapide (Juxtapid™) is the first and only medication in this class. It is approved for a specific genetic high cholesterol disorder known as homozygous familial hypercholesterolemia (HoFH).
This medication may be prescribed and dispensed only by healthcare providers and pharmacies that have been specially certified to do so, due to the potentially serious risks associated with its use. In particular, lomitapide can cause serious liver problems. It also has several significant drug interactions, and dosing is not particularly straightforward (people must start with a low dosage and gradually increase to a higher one).
Approved in January 2013, mipomersen (Kynamro™) is the first and only medication in this class. It is approved for a specific genetic high cholesterol disorder known as homozygous familial hypercholesterolemia (HoFH). It is given as an injection just under the skin (a subcutaneous injection) once a week and is intended for use in combination with other cholesterol medications. Like many other cholesterol medications, mipomersen can cause serious liver problems, and careful monitoring of the liver (using routine blood tests) is recommended.
Cholesterol is not a bad thing -- it serves an important purpose in keeping the body healthy.
Unfortunately, some people who have high cholesterol choose to ignore it, because there are no obvious symptoms. Having high levels of cholesterol for long periods of time can greatly increase your risk of serious medical problems, like heart disease, stroke, atherosclerosis, and other heart and blood vessel problems.
Controlling cholesterol can be a challenge, but commitment and care from you and your healthcare providers can make a difference. Making a lifelong commitment to lower your high cholesterol is a worthy goal.